Condition/Disease
* Percentage of mCRPC participants who have not used ARPI and whose PSA has decreased by ≥90% from baseline.* Incidence of no mineral corticosteroid toxicity (defined as no ≥ Grade 1 hypokalemia and no ≥ Grade 2 hypertension).* Percentage of mHSPC participants with PSA ≤ 0.2 ng/mL at 8 months.* DLT, AE, SAE, laboratory test results (including chemistry, hematology, and urinalysis), ECG, vital signs, physical examination, and ECOG performance status score.
